Medifast (NYSE:MED) Releases Q3 2025 Earnings Guidance

Key Points

• Medifast has issued Q3 2025 earnings guidance with an anticipated EPS range of -0.600 to 0.00, which is lower than the consensus estimate of -0.300.
• The company's revenue forecast for the period is between $70.0 million and $90.0 million, below the consensus estimate of $93.8 million.
• Medifast's stock has decreased by 1.8%, trading at $13.50, amidst recent updates and analyst upgrades to a "buy" rating.

Medifast (NYSE:MED - Get Free Report) updated its third quarter 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of -0.600-0.00 for the period, compared to the consensus estimate of -0.300. The company issued revenue guidance of $70.0 million-$90.0 million, compared to the consensus revenue estimate of $93.8 million.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Medifast from a "hold" rating to a "buy" rating in a research report on Thursday, May 1st.

Medifast Stock Down 2.4%

Shares of Medifast stock traded down $0.31 during trading on Wednesday, reaching $12.76. 134,576 shares of the company were exchanged, compared to its average volume of 230,083. Medifast has a twelve month low of $11.57 and a twelve month high of $21.98. The business has a 50-day moving average price of $13.91 and a 200-day moving average price of $13.94. The firm has a market capitalization of $140.23 million, a price-to-earnings ratio of 39.86 and a beta of 0.80.

Medifast (NYSE:MED - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The specialty retailer reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.26. Medifast had a net margin of 0.76% and a return on equity of 2.02%. The company had revenue of $105.56 million for the quarter, compared to analyst estimates of $96.10 million. On average, equities research analysts forecast that Medifast will post 0.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MED. AQR Capital Management LLC increased its stake in Medifast by 14.5% during the 1st quarter. AQR Capital Management LLC now owns 199,750 shares of the specialty retailer's stock valued at $2,693,000 after purchasing an additional 25,366 shares in the last quarter. Amundi increased its stake in Medifast by 43.5% during the 1st quarter. Amundi now owns 30,439 shares of the specialty retailer's stock valued at $398,000 after purchasing an additional 9,224 shares in the last quarter. Finally, Strs Ohio bought a new stake in Medifast during the 1st quarter valued at $78,000. Institutional investors and hedge funds own 95.51% of the company's stock.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.